Cost-effectiveness of venous thrombosis prophylaxis following ischemic stroke: an assessment of currently available literature.
Wade
W E
WE
College of Pharmacy, University of Georgia, Athens 30602, USA. bwade@rx.uga.edu
D002545:Brain Ischemia / Q000150:complications* / Q000191:economics*; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D017985:Dalteparin / Q000627:therapeutic use; D003871:Dermatan Sulfate / Q000627:therapeutic use; D004338:Drug Combinations; D006493:Heparin / Q000627:therapeutic use; D006497:Heparan Sulfate / Q000627:therapeutic use; D006801:Humans; D016239:MEDLINE; D013924:Thrombophlebitis / Q000209:etiology / Q000517:prevention & control*
D002809:Chondroitin Sulfates; D017985:Dalteparin; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid